Fig. 4
PKM2 Knockdown Sensitizes Cells to Chemotherapy and Improves TACE Response In Vitro: (a) PKM2 knockdown results in a significant decrease in the IC50 of doxorubicin in hypoxia in both responder and non-responder like cell lines (b) PKM2 knockdown results in a significant decrease in the IC50 of cisplatin in hypoxia in both responder and non-responder like cell lines (c) In vitro TACE assay measuring cellular proliferation at 72 h in hypoxia after the administration of doxorubicin at cell specific IC50. TACE responder like cells (left) have a significant reduction in cellular proliferation when treated with doxorubicin alone unlike TACE non-responder like cells (right) which have little to no response. TACE non-responder like cells overcome doxorubicin resistance in hypoxia with the addition of a PKM2 knockdown (d) Relative change in cellular proliferation demonstrating improvement of TACE efficacy in responder like cells and therapeutic reprogramming in TACE non-responders with shPKM2